Equities Analysts Set Expectations for XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at Leerink Partnrs lowered their FY2026 EPS estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of ($3.54) for the year, down from their previous estimate of ($3.40). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.05). During the same period last year, the business earned ($0.72) earnings per share.

Several other brokerages also recently commented on XENE. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Wedbush lowered their price objective on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $57.45.

Xenon Pharmaceuticals Trading Up 1.6 %

Xenon Pharmaceuticals stock opened at $43.31 on Friday. The firm has a market capitalization of $3.27 billion, a P/E ratio of -15.98 and a beta of 1.25. The business has a 50-day moving average of $39.90 and a 200-day moving average of $40.16. Xenon Pharmaceuticals has a 1 year low of $27.99 and a 1 year high of $50.99.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Blue Trust Inc. raised its stake in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 641 shares in the last quarter. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals during the third quarter worth $102,000. Handelsbanken Fonder AB raised its position in Xenon Pharmaceuticals by 8.1% during the third quarter. Handelsbanken Fonder AB now owns 22,700 shares of the biopharmaceutical company’s stock worth $894,000 after acquiring an additional 1,700 shares in the last quarter. Point72 Asset Management L.P. raised its position in Xenon Pharmaceuticals by 74.7% during the second quarter. Point72 Asset Management L.P. now owns 482,022 shares of the biopharmaceutical company’s stock worth $18,794,000 after acquiring an additional 206,163 shares in the last quarter. Finally, Quarry LP lifted its stake in Xenon Pharmaceuticals by 207.7% in the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 2,700 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.